Besponsa
Payments companies reported to CMS as associated with Besponsa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Besponsa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Besponsa
These are the largest totals companies reported as associated with Besponsa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Elias Jabbour | Houston, TX | Hematology & Oncology | $22,540.57 |
| Noopur Raje | Boston, MA | Internal Medicine | $11,592.77 |
| Jae Park | New York, NY | Hematology & Oncology | $10,061.92 |
| Harry Erba | Ann Arbor, MI | Medical Oncology | $9,028.22 |
| Aaron Logan | San Francisco, CA | Hematology & Oncology | $7,898.06 |
| Marcos De Lima | Cleveland, OH | Hematology & Oncology | $7,643.99 |
| Ibrahim Aldoss | Duarte, CA | Hematology (Internal Medicine) | $7,263.22 |
| Ryan Cassaday | Seattle, WA | Hematology & Oncology | $6,220.00 |
| Partow Kebriaei | Houston, TX | Hematology & Oncology | $5,474.00 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $5,370.51 |
Prescribed Besponsa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.